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The increasing number of nosocomial pathogens with resistances against last resort antibiotics like linezolid
leads to a pressing need for the reliable detection of these drug-resistant bacteria. National guidelines on
infection prevention, e.g., in Germany, have already recommend screening for linezolid-resistant bacteria,
although a corresponding screening agar medium has not been provided. In this study we analyzed the per-
formance and reliability of a commercial, chromogenic linezolid screening agar. The medium was capable to
predict more than a hundred linezolid-resistant isolates of E. faecium, E. faecalis, S. aureus, S. epidermidis, and
S. hominis with excellent sensitivity and specificity. All isolates were collected at the National Reference Cen-
tre between 2010 and 2020.
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Last resort antibiotics such as linezolid, tigecycline, and daptomy-
cin are therapeutic alternatives for the treatment of infections with
multidrug-resistant staphylococci and enterococci including methi-
cillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant
Staphylococcus epidermidis (MRSE), and vancomycin-resistant entero-
cocci (VRE). Although an increased use of these substances has
already led to increasing rates of resistance, corresponding studies
that show a clear association between use and resistance progression
are limited to single institutions (Bai et al., 2019; Jian et al., 2020;
Wessels et al., 2018; Zou and Xia, 2020).
Linezolid is a synthetic oxazolidinone antibiotic that is active
against most multidrug-resistant, clinical isolates of staphylococci,
and enterococci such as MRSA, MRSE and VRE. Although linezolid
was already approved for commercial use in 2000, resistance surveil-
lance schemes and systems did not report increasing linezolid resis-
tance in clinical isolates over time ((ECDC) 2020; Heininger et al.,
2020; Markwart et al., 2019; Pfaller et al., 2019; Walter et al., 2015;
Walter et al., 2017; Zou and Xia 2020). However, in recent years a
trend toward an increased prevalence of linezolid resistance in clini-
cal E. faecium and S. epidermidis isolates has been recognized at the
German National Reference Centre for Staphylococci and Enterococci,
while the numbers of linezolid-resistant S. aureus remained stable(Klare et al., 2015; Klare et al., 2019; Layer et al., 2019). Therefore, ref-
erence laboratories may play an important role in the early recogni-
tion of upcoming resistance trends before they might get noticed in
surveillance schemes (Klare et al., 2015; Klare et al., 2019;
Layer et al., 2019).
In contrast to most protein synthesis inhibitors, linezolid targets
the 23S ribosomal DNA of the 50S subunit, thus preventing the for-
mation of a functional 70S-initiation complex. In staphylococci and
enterococci, development of oxazolidinone resistance has been asso-
ciated with mutations in 23S rDNA alleles (Bender et al., 2018; Ruiz-
Ripa et al., 2020; Sadowy, 2018). Additionally, variations in ribosomal
protein genes may occur (Bender et al., 2018; Rouard et al., 2017). A
reservoir of transferable linezolid resistance genes was selected in
animal farming and reported for nonclinical isolates of E. faecium and
E. faecalis and coagulase-negative staphylococci, coded by cfr (includ-
ing cfr(B)) and/or optrA (Cuny et al., 2017; Wang et al., 2015). Corre-
sponding resistance determinants were also reported in enterococcal
and staphylococcal isolates from healthy humans and hospitalized
patients (Bender et al., 2018; Chen et al., 2019; Cai et al., 2019;
Deshpande et al. 2018; Elghaieb et al., 2020; Gawryszewska et al.,
2017; Zhou et al., 2019). In 2018, the novel linezolid resistance gene
poxtA was first described from a clinical MRSA in Italy
(Antonelli et al., 2018) and later demonstrated to be wider distrib-
uted among enterococci of various origins (Bender et al., 2019;
Egan et al., 2020; Elghaieb et al., 2019; Freitas et al., 2020). However,
it is not entirely clear whether these transferable resistance determi-
nants can mediate linezolid resistance in various strain backgrounds,
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tance in E. faecium or E. faecalis (Bender et al., 2016; Liu et al., 2014).
An important step in preventing the dissemination of linezolid-
resistant staphylococci and enterococci in the nosocomial setting is
the reliable identification and early recognition of colonized hosts. In
2018, the German Commission for Hospital Hygiene and Infection
Prevention (KRINKO) published a recommendation for the preven-
tion of infections with “enterococci with special antibiotic resistan-
ces” (KRINKO, 2018). The guideline recommended screening for
linezolid-resistant enterococci (LRE), when more than a single case is
notified within 3 months and an epidemiological link cannot be
excluded. However, the technical implementation of an appropriate
screening has not been specified. In the last 2 years 2 studies intro-
duced screening agar media for the detection of linezolid-resistant
staphylococci and enterococci. The first study, published by Nord-
mann et al., introduced a selective screening agar called “SuperLine-
zolid” medium (Nordmann et al., 2019). The authors used a non-
selective Mueller-Hinton agar supplemented with aztreonam, colistin
and amphothericin B to suppress the normal flora and a linezolid
concentration of 1.5 mg/L. The study sample mainly included S. epi-
dermidis isolates, for which, performance was very good. In the same
year, Werner et al. introduced a selective LRE screening agar, which
was based on EnterococcoselagarTM supplemented with 2 mg/L line-
zolid. Reliable screening to detect all LRE required a prolonged incu-
bation of up to 48 h at 37°C (Werner et al., 2019). The agar revealed a
sensitivity and specificity of 96.6% and 94.4%, respectively.
With the present study we assessed the performance of a novel,
commercial screening agar called CHROMagarTM LIN-R. The agar
allows a species- and genus-specific diagnostics based on a cleavage
of chromogenic substrates and a detection of linezolid-resistant
staphylococci and enterococci by a supplementation of linezolid. We
tested this agar with a well-characterized collection of 48 clinical
enterococci (40 E. faecium (29 linezolid-resistant [LIN-r]), 8 E. faecalis
(7 LIN-r), 17 S. aureus isolates (14 LIN-r) and 70 coagulase-negative
staphylococci (50 S. epidermidis (39 LIN-r), 20 S. hominis (15 LIN-r)).
2. Materials and methods
2.1. Strain collection
For CHROMagarTM LIN-R validation, we included 40 isolates of
E. faecium (29 LIN-r) and 8 of E. faecalis (7 LIN-r). These strains have
already been described and used in a previous assay validation
(Werner et al., 2019). In addition, we compiled the following staphy-
lococcal isolates’ collection: 17 S. aureus (14 LIN-r), 50 S. epidermidis
(all methicillin-resistant [MRSE]; 39 LIN-r), and 20 S. hominis (15 line-
zolid- and methicillin-resistant [MRSH]; 5 linezolid- and methicillin-
susceptible [MSSH]). Isolates were partly described in recent publica-
tions (Bender et al., 2015; Layer et al., 2018; Wessels et al., 2018). All
isolates had been sent previously from diagnostic laboratories to the
National Reference Centre for strain characterization, typing and/or
resistance confirmation as part of the routine work of the reference
center activities (Supplementary Table S1). The following reference
isolates were used: E. faecalis ATCC 29212, E. faecium ATCC 19434T, S.
aureus ATCC 25923, and E. coli ATCC 25922.
2.2. Susceptibility testing
Susceptibilities to vancomycin and linezolid were determined by
broth microdilution using cation-adjusted Mueller-Hinton broth
(Becton-Dickinson, Heidelberg, Germany) according to EUCAST
guidelines (EUCAST v8 to v10). Oxacillin resistance was deduced
from results of a cefoxitin screen, oxacillin broth dilution MICs
according to EUCAST and the detection of the mecA gene by PCR.
Linezolid resistance is defined as R >4 mg/L for Enterococcus spp. and
Staphylococcus spp. In case of contradictory results, linezolid MICresults were additionally confirmed by Etest (bioMerieux, Nuertin-
gen, Germany).
2.3. Determination of resistance genotypes
Genetic determinants coding for vancomycin resistance in E. fae-
cium (vanA, vanB) and oxacillin resistance in S. aureus (mecA) were
identified by the use of multiplex PCR (Bender et al., 2015;
Bender et al., 2018). For enterococcal isolates, 23S rDNA mutations
were determined by an amplification-restriction-based procedure as
described recently (Werner et al. 2004). Additionally, the presence of
the transferable LIN-r resistance genes cfr(B), optrA and poxtA was
assessed using a multiplex PCR (Bender et al., 2019). For isolates
where whole genome sequence data were available, we used LRE
Finder to confirm the genetic basis of linezolid resistance in entero-
cocci (Hasman et al., 2019). Staphylococcal isolates were screened for
presence of the cfr gene by PCR according to (Kehrenberg and
Schwarz, 2006). For S. aureus strains genes, encoding the central loop
of domain V of 23S rRNA, were analyzed for mutations conferring
linezolid resistance (Tsiodras et al., 2001). Detailed information can
be found in Supplementary Table S1.
2.4. Testing CHROMagarTM LIN-R plates
All isolates were tested on CHROMagarTM LIN-R. CHROMagar LIN-r is
a brand of CHROMagar (Paris, France), which is distributed in Germany
by MAST Diagnostica (Heidelberg, Germany). In brief, 10 mL of a freshly
prepared bacterial suspension of McFarland 0.5 (approximately
1.5£ 106 CFU) were inoculated onto the agar plates. Cell density was in
a range that allowed single colony growth after streaking the sample
out. Growth, colony morphology and color were determined after
24 hours (overnight) and 48 hours (2d) at 35 to 37°C.
2.5. Statistical analyses
Statistical values were calculated according to https://www.med
calc.org/calc/diagnostic_test.php.
3. Results and discussion
3.1. Validating CHROMagarTM LIN-R for enterococci
All linezolid-susceptible reference isolates performed accordingly
on CHROMagar LIN-R (no growth after 48 hours). Out of 48 E. faecium
and E. faecalis isolates, 47 performed as expected on CHROMagar LIN-
R: While 35 of 36 linezolid-resistant enterococcal isolates grew on
CHROMagar, 12 linezolid-susceptible isolates showed no growth.
Importantly, to predict a correct screening result, an incubation of up
to 48 hours was required. Growth of linezolid-resistant enterococci
was delayed on CHROMagar LIN-R revealing only a slight growth
after overnight incubation, meaning that growth was not visible as
single colonies and colony color was not fully expressed (Fig. 1). A
prolonged incubation was also required with the LRE screening agar
introduced recently (Werner et al., 2019). For trained and experi-
enced personal a differentiation based on colony color was possible
for E. faecalis (turquoise blue) and E. faecium (dark blue) (Fig. 1).
A single E. faecium isolate UW19492 with an initial linezolid MIC
of 8 mg/L (broth microdilution; LIN-r) did not grow on CHROMagar
LIN-R. Repeated susceptibility testing by broth microdilution and
Etest revealed contradictory MIC results for the respective isolate
(broth microdilution: 4 mg/L (LIN-s) and 8 mg/L (LIN-r); Etest: 3 mg/L
(LIN-s)). A molecular analysis of this isolate revealed no transferable
linezolid resistance determinant and a 23S rDNA alleles’ ratio of 4
(wildtype) to 2 (mutant). A wildtype to mutant 23S rDNA alleles’ ratio
of 4:2 is mostly associated with phenotypic linezolid resistance
(Marshall et al., 2002; Werner et al., 2019). Due to these conflicting
Fig. 1. Growth behavior of linezolid-resistant isolates of E. faecium, E. faecalis, S. aureus and S. epidermidis. E. faecium with linezolid (LIN) MICs of 8 (A) and 32 mg/L (B) after over-
night incubation. E. faecalis (C; LIN MIC = 32 mg/L) and E. faecium (D; LIN MIC = 8 mg/L) grown for 48 hours. Isolates of S. aureus grown for 24 hours (E; LIN MIC = 16 mg/L) and (F,
LIN MIC = 8 mg/L) and 48 hours (G, H; LIN MICs = 8 mg/L). Isolates of S. epidermidiswith LIN MICs of >16 mg/L after 48 hours (I,J).
Table 1
Performance of CHROMagarTM LIN-R to identify linezolid-resistant staphylococci and enterococci.
Bacterium LIN-r LIN-s Grown Not grown Specificity (%) 95% CI (%) Sensitivity(%) 95% CI (%)
Enterococcus spp., n = 47* 35 12 35 12 100% 73.5−100 100% 90−100
S. aureus, n = 17 13 4 13 4 100% 47.8−100 100% 73.5−100
S. epidermidis, n = 50 39 11 38 12 100% 71.5−100 97.4% 86.5−99.94
S. hominis, n = 20 15 5 15 5 100% 47.8−100 100% 78.2−100
Sum 101 33 100 34 100% 89.7−100 99.01 94.6−99.97
E. faecium and E. faecaliswere summarized as Enterococcus spp. LIN-r/-s, linezolid-resistant/-susceptible.
* An E. faecium isolate which appeared linezolid-resistant (8 mg/L) and linezolid-susceptible (4 mg/L) in repeated MIC tests and with different methods could not be categorized
and thus was excluded from this analysis.
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late unambiguously as LIN-r or LIN-s and have excluded it from sub-
sequent analyses and calculations (Table 1).
3.2. Validating CHROMagarTM LIN-R for staphylococci
All 4 linezolid-susceptible S. aureus isolates did not grow on CHRO-
Magar LIN-R after up to 48 hours incubation at 35 to 37°C. As expected
16 of 17 linezolid-resistant S. aureus isolates grew on CHROMagar LIN-R
(Table 1). The morphology of S. aureus colonies was mainly character-
ized by yellowish-pink colony color (Fig. 1). A single isolate with an ini-
tial linezolid MIC of 8 mg/L (LIN-r) showed no colony formation on the
screening agar. In repeated MIC determinations the isolate revealed
linezolidMIC values of 2 and 4mg/L (LIN-s). Subsequentmolecular anal-
yses revealed a loss of the cfr encoding resistance plasmid. This single
case demonstrates the excellent predictive power of the tested screen-
ing agar by identifying an isolate with an incorrect categorization which
has been re-tested and then re-classified as “linezolid-susceptible”.
All eleven linezolid-susceptible S. epidermidis and 5 linezolid-sus-
ceptible S. hominis isolates did not grow on CHROMagar LIN-R after
48 hours incubation at 35 to 37°C. Altogether 42 of 43 linezolid-resis-
tant S. epidermidis and S. hominis isolates grew on CHROMagar LIN-R.
A single S. epidermidis isolate showed no colony formation but
revealed a broth microdilution MIC of 16 mg/L (LIN-r) and an Etest
MIC of 12 mg/L in repeated tests. Thus, this result must be considered
“false negative”. Growth of coagulase-negative staphylococci was
mainly characterized by whitish-pink colonies (mainly white colo-
nies and a pink surrounding; Fig. 1).
3.3. Comparison to previously published linezolid screening media
In 2019, Nordmann et al. introduced a Super Linezolid agar which
is based on Mueller-Hinton agar supplemented with 1.5 mg/L line-
zolid. The medium was additionally supplemented with aztreonam(2 mg/L), colistin (15 mg/L) and amphotericin B (5 mg/L) to suppress
microorganisms of the normal intestinal flora. The agar was supposed
to be used to detect linezolid-resistant Gram-positive bacteria. How-
ever, the collection contained primarily linezolid-resistant S. epider-
midis (n = 13) and only a limited number of linezolid-resistant
isolates of other genera and species such as S. aureus (n = 2), S. capitis
(n = 1), and E. faecium (n = 1). Due to the low number of isolates other
than S. epidermidis, a general assumption about performance of this
agar with a concentration of linezolid of 1.5 mg/L cannot be made.
Recently, our group introduced a LRE screening agar which was based
on an enterococcal screening agar (EnterococcoselagarTM, Becton-
Dickinson, Heidelberg, Germany) supplemented with 2 mg/L linezolid
(Werner et al., 2019). The agar was validated with several reference
strains and 48 well-characterized enterococcal isolates (the same that
were used for this study), which revealed a high sensitivity (98.8%)
and specificity (100%). A feasibility study using 400 swab samples of
enterococci sent to the Reference Centre for further analyses but of
unknown linezolid status also revealed good results. An application
study with a clinical partner is currently underway and preliminary
results confirm the good specificity and sensitivity of predicting LRE
directly from swabs (Weber et al., unpublished results).
There are reports about staphylococcal and enterococcal isolates
containing linezolid resistance genes and which exhibited linezolid
MICs of 4 mg/L or less (interpreted as linezolid-susceptible) (Li et al.,
2015; Wardenburg et al., 2019). Whereas the clinical significance of
this observation remains to be determined, it is obvious that such iso-
lates represent a diagnostic challenge in general and in particular for
the present CHROMagarTM LIN-R and all other corresponding screen-
ing agar media.
4. Conclusion
The present study includes the largest number of linezolid-resis-
tant isolates of Enterococcus spp. and Staphylococcus spp. which has
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CHROMagar LIN-R demonstrated an excellent performance to selec-
tively grow linezolid-resistant isolates of E. faecium, E. faecalis,
S. aureus, S. epidermidis and S. hominis while retaining sufficient spec-
ificity to suppress growth of linezolid-susceptible variants of the
same species also after incubation of up to 48 hours and at 35 to 37°
C. Summarizing all available data from this study, the agar revealed a
specificity of 100% and a sensitivity of 99% (Table 1). Even species pre-
diction from plates after 2 times overnight incubation was possible
for the experienced and trained expert (Fig. 1). We did not recognize
growth differences in relation to the linezolid MIC or a corresponding
linezolid resistance mechanism. However, about half of the linezolid-
resistant staphylococci already demonstrated single colony growth
after overnight incubation, whereas the other half and almost all line-
zolid-resistant enterococci required longer incubation of up to 2
times overnight. The CHROMagar LIN-r will be commercially avail-
able soon. The instruction leaflet (package insert) will consider the
results of the internal and external (this study) evaluations. Further
analysis must now prove performance under routine clinical condi-
tions with swab samples taken from hospital patients.
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